User profiles for Fahrettin Covut
 | Fahrettin CovutUniversity of Wisconsin Verified email at uwhealth.org Cited by 541 |
[HTML][HTML] Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study
Background Tocilizumab was approved for chimeric antigen receptor T–cell therapy
induced cytokine release syndrome and it may provide clinical benefit for selected COVID–19 …
induced cytokine release syndrome and it may provide clinical benefit for selected COVID–19 …
Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study
The IMPEDE VTE score has recently emerged as a novel risk prediction tool for venous
thromboembolism (VTE) in multiple myeloma (MM). We retrospectively reviewed 839 patients …
thromboembolism (VTE) in multiple myeloma (MM). We retrospectively reviewed 839 patients …
[PDF][PDF] Prevalence and predictors of gastrointestinal dysmotility in patients with hypermobile Ehlers-Danlos syndrome: a tertiary care center experience
Ehlers-Danlos syndrome (EDS), specifically the hypermobility type (hEDS), is associated
with a variety of gastrointestinal (GI) conditions. This study aims to evaluate the prevalence …
with a variety of gastrointestinal (GI) conditions. This study aims to evaluate the prevalence …
Apixaban and rivaroxaban in patients with cerebral venous thrombosis
Cerebral venous thrombosis (CVT) affects approximately 15 people per million annually
and represents 0.5% of all stroke [1, 2]. Initiation of anticoagulation with heparin followed by …
and represents 0.5% of all stroke [1, 2]. Initiation of anticoagulation with heparin followed by …
Mitigating the risk of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory-based therapy
F Covut, KM Sanfilippo - Hematology, 2022 - ashpublications.org
Patients with multiple myeloma (MM) have up to a 20-fold increased risk of venous thromboembolism
(VTE) compared with the general population, with most events occurring within the …
(VTE) compared with the general population, with most events occurring within the …
Bispecific antibodies for the treatment of multiple myeloma
SR Goldsmith, S Streeter, F Covut - Current Hematologic Malignancy …, 2022 - Springer
Purpose of Review Advances in multiple myeloma therapies have greatly improved outcomes
for patients living with the disease, although to date there is yet to be a cure. Cellular and …
for patients living with the disease, although to date there is yet to be a cure. Cellular and …
Racial and age-related disparities in early mortality affect the outcomes of multiple myeloma patients
Multiple myeloma (MM) is an incurable hematologic malignancy with disparities in outcomes
noted among racial-ethnic subgroups [1, 2]. A number of prior studies comparing overall …
noted among racial-ethnic subgroups [1, 2]. A number of prior studies comparing overall …
Duvelisib for critically Ill patients with coronavirus disease 2019: An investigator-initiated, randomized, placebo-controlled, double-blind pilot trial
SR Goldsmith, F Covut, M Fiala, Z Xiang… - Open Forum …, 2023 - academic.oup.com
Background Despite improvements in prevention and treatment, severe coronavirus
disease 2019 (COVID-19) is associated with high mortality. Phosphoinositide 3-kinase (PI3K) …
disease 2019 (COVID-19) is associated with high mortality. Phosphoinositide 3-kinase (PI3K) …
Impact of lenalidomide on collected hematopoietic myeloid and erythroid progenitors: peripheral stem cell collection may not be affected
Abstract Lenalidomide (LEN) is commonly used as part of induction therapy in transplant-eligible
patients with multiple myeloma. However, LEN use is associated with increased …
patients with multiple myeloma. However, LEN use is associated with increased …
Low dose anti-thymocyte globulin reduces chronic graft-versus-host disease incidence rates after matched unrelated donor transplantation
A Tandra, F Covut, B Cooper, R Creger… - Leukemia & …, 2018 - Taylor & Francis
Anti-thymocyte globulin (ATG) is often added to hematopoietic stem cell transplant conditioning
regimens to prevent graft rejection and reduce graft-versus-host disease (GVHD). Doses …
regimens to prevent graft rejection and reduce graft-versus-host disease (GVHD). Doses …